<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047186</url>
  </required_header>
  <id_info>
    <org_study_id>2019CR107</org_study_id>
    <nct_id>NCT04047186</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules</brief_title>
  <official_title>Neoadjuvant Anti-PD-1 Therapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous&#xD;
      Ground-glass Nodules: a pilot study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In many cases, non-small-cell lung cancer(NSCLC) manifested as synchronous ground-glass&#xD;
      nodules(GGNs) and makes complete surgical resection impossible. At the same time, there is no&#xD;
      good solution for the remaining GGNs after resection of the main lesion. Theoretically,&#xD;
      pre-operative anti-PD-1 therapy is optimal for promoting anti-tumor immune response on the&#xD;
      basis of maximum tumor mutational burden (TMB). In addition, neoadjuvant immunotherapy should&#xD;
      have long-term anti-tumor effect even after surgery, because tumor recurrence may cause&#xD;
      memory cells activation and differentiation. This is a pilot study to analysis the&#xD;
      pathological remission rate of neoadjuvant immunotherapy and adverse events related to the&#xD;
      treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological response rate</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment-related adverse events</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Pulmonary Nodules</condition>
  <arm_group>
    <arm_group_label>neoadjuvant PD-1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving neoadjuvant therapy of programmed death-1 (pd-1) immune checkpoint inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab Injection</intervention_name>
    <description>Nivolumab 3mg/kg on day-28 and day-14 prior to planned surgical resection</description>
    <arm_group_label>neoadjuvant PD-1 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  not less than two GGNs on chest CT&#xD;
&#xD;
          -  at least one lesion is diagnosed as NSCLC from biopsy pathology&#xD;
&#xD;
          -  no contraindication for surgery&#xD;
&#xD;
          -  ECOG score of 0 or 1&#xD;
&#xD;
          -  no detectable evidence of distant metastasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  medical history of malignancy&#xD;
&#xD;
          -  pregnant or breeding period&#xD;
&#xD;
          -  severe organ failure (heart, liver, kidney, and lung)&#xD;
&#xD;
          -  high risk of cerebral-cardiovascular evens&#xD;
&#xD;
          -  infection out of control&#xD;
&#xD;
          -  received or receiving chemo- and radiotherapy&#xD;
&#xD;
          -  history of severe reaction due to allergy or hypersensitivity&#xD;
&#xD;
          -  severe mental disorder&#xD;
&#xD;
          -  currently been enrolled in other trials&#xD;
&#xD;
          -  autoimmune or chronic inflammatory disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiangning Fu, MD</last_name>
    <phone>+8613607150390</phone>
    <email>fuxn2006@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shu Peng, PhD</last_name>
    <phone>+8618571716422</phone>
    <email>drpeng90@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Huazhong Technology Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiangning Fu, MD</last_name>
      <phone>0086-13607150390</phone>
      <email>Fuxn2006@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Shu Peng, PhD</last_name>
      <phone>0086-18571716422</phone>
      <email>drpeng90@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 4, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>Multiple Pulmonary Nodules</keyword>
  <keyword>Lung Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>According to regulation of institution, IPD can not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

